Delivery Order SPE2DB22D1200-SPE2DB25FN4HM
- Not listed
- The Defense Logistics Agency awarded a $4,008.81 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with an August 4, 2025 completion date. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves as the prime contractor...
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $31,936.11 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on September 8, 2025, with an ultimate completion date of September 9, 2025. This non-competitive delivery order was issued from AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global...
- The Defense Logistics Agency awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside delivery order executed by the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) valued at $17,437.44. This firm fixed-price delivery order, which is expected to be completed by September 10, 2025, represents a non-set-aside competitive procurement. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a $28,416.82 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award carries no set-aside designation, reflecting the company's proven capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets in a quantity of 30 units, with a ceiling value of $87,792.14. This firm fixed-price delivery order, awarded on July 23, 2025, represents a non-set-aside competitive award with an ultimate completion date of July 24, 2025. The pharmaceutical products will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and...
- The Defense Logistics Agency awarded a $3,173.42 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 13, 2025, with an ultimate completion date of August 14, 2025. This non-competitive, non-set-aside contract represents a routine pharmaceutical procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The delivery location is AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) under a firm fixed-price contract valued at approximately $12.0K. This award, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The order will be fulfilled from the contractor's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $42,368.91 to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The place of...
- SPE2DB22D1200Indefinite Delivery Contract
- SPE2DB22D1200-SPE2DB25FN4HMDelivery Order
The Defense Logistics Agency awarded a $26,705.50 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. This non-competitive delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is well-positioned to fulfill this requirement as a leading supplier to military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The parent IDC enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, including the Defense Health Agency and U.S. Coast Guard. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the specialized pharmaceutical support AmerisourceBergen provides to federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.7k | 9/10/25 |